Zydus Lifesciences saw its shares rise 1% to ₹1,088.85 on September 30, following the US FDA's approval of Enzalutamide capsules, used to treat metastatic prostate cancer.
The drug, valued at $870 million, will be produced at the company's Ahmedabad facility. Zydus has seen a 76% surge in stock over the past year, pushing its market value to ₹1.1 lakh crore, outperforming the Nifty 50's 34% gain.